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Summary
Intradermal administration ofrecombinant interferony (rIFN-y) to lepromatous leprosy patients
has converted the local histology toward a tuberculoid pattern . However, such changes have been
confined to the site of injection . In contrast, in the present study, marked, intradermal accumulation
of CD3+, CD4+, CD8+, and CDla+ T cells and Leu-M5+ mononuclear phagocytes was
induced at a distance from the sites of administration, in a dose-dependent manner, by 10 daily
intramuscular injections of 10-30 hg rIFN-y/m 2 . Mononuclear cell infiltration began within
3 d of onset of rIFN-y therapy and persisted at least 8 wk . Intramuscular administration of
rIFN-y to lepromatous patients receiving concurrent chemotherapy can safely induce widespread
histologic features of an upgrading reaction .
prosy, the first disease associated with a specific bacte-
rium (1) and one of the first to be treated with chemo-
therapy (2), remains one of the most prevalent life-threatening
infections. The lepromatous form of the disease is marked
by anergy to the causative organism Mycobacterium leprae,
a paucity of infiltrating lymphocytes, and widespread prolifer-
ation ofthe bacterium within macrophages in the skin . De-
spite years of multi-drug therapy, cure is not often achieved .
In contrast, patients with the tuberculoid form ofthe disease
display vigorous delayed-type hypersensitivity; the lesions are
rich in activated T cells and macrophages, which markedly
restrict the proliferation ofthe organism; and cure is attained
routinely, sometimes even without chemotherapy (3) . In effect,
tuberculoid leprosy illustrates what immunotherapy might
hope to achieve in lepromatous leprosy.
Over the past 18 yr, injection of at least six different im-
munologically active agents has been reported to induce tuber-
culoid features (partial or complete upgrading reactions) in
lepromatous patients,either systemically (4, 5) or at the sites
of injection (6-12) . These agents were allogeneic lympho-
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cytes (4); transfer factor (5); mixtures ofM. leprae orM . leprae-
murium with BCG (6) ; rIFN-y (7-10); purified protein deriva-
tive (11) ; and 111,2 (12) . Of these, rIFN-y has been studied
most widely, based on the rationale that it is preferable to
use a defined, standardized agent, and that lepromatous leprosy
can be viewed, in part, as an antigen-specificIFN-y deficiency
state, resulting in failure to activate macrophages (7) . Four
studies involving 96 patients in the United States, Brazil,
Africa, and India have given a consistent picture: one to five
intradermal injections of 1-20Ag rIFN-y induced local con-
version from a lepromatous to a more tuberculoid histology,
with rapid local reduction in apparent bacterial burden in
28 of 42 cases evaluated (67%) (7-10) .
Lepromatous disease affects nearly the entire dermis, while
the changes induced by intradermal injection of rIFN-y have
been confined to the site of injection (10) . Thus, the fore-
going results appeared to hold little therapeutic promise, unless
more frequent administration and/or higher doses ofrIFN-y
can be shown to induce a more widespread response. How-
ever, it has been feared that any attempt to achieve bioactive
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precipitate or exacerbate destructive immunologic reactions
that occur frequently in leprosy. The present study demon-
strated that a 10-d course ofintramuscular rIFN-y in leproma-
tous patients had little toxicity, yet inducedlong-lasting, wide-
spread, intradermal accumulation of mononuclear leukocytes.
This opens the door to studies of rIFN-y in leprosy with
curative intent .
Materials and Methods
rIFN-y.
￿
rIFN-y (Genentech, Inc ., South San Francisco, CA)
was purified from Escherichia coli transfected with the cDNA for
human rIFN-y; specific activity was 2 x 10' U/mg . The lyophi-
late was reconstituted in sterile distilled water to a concentration
of 200 FAg/ml .
Study Design .
￿
Eightmen and three women 32-76 yr old were
diagnosed by skin biopsy at least 6 mo before the study as having
borderline or polar lepromatous leprosy by Ridleyjopling criteria
(3) . Their pre-study medications (Dapsone, Rifampin, clofazimine,
and/or thalidomide) were continued.
Single Injections.
￿
In three subjects, 3-mm punch biopsies were
taken from both buttocks, followed by one intra-deltoid injection
of 10 or 30 Wg of rIFN-y/mz . 2 d later, a third skin biopsy was
taken from the buttocks.
Multiple Injections.
￿
Four subjects were studied at each of two
rIFN-y dose levels : 10 or 30 lAg/m2 per day . Control 4-mm punch
biopsies were taken from the skin ofboth buttocks. Beginning the
same day, the patients received 10 daily intra-triceps injections of
rIFN-,y in alternate arms . Skin biopsies were taken again from the
buttocks or lower back on day 4 (one biopsy), day 11 (bilateral
biopsies), 3 wk after the end of rIFN-y injections (one biopsy),
and 6wk after the end of rIFN-,y injections (one biopsy) . Of the
seven biopsies, three were from one side of the patient and four
from the other side. Physical examination, weight, and vital signs
were recorded daily. On days 1 and 11, the following were moni-
tored : sensory nerve conduction velocity, chest x-ray, electrocardi-
ogram, urinalysis, hemogram, prothrombin time, partial throm-
boplastin time, and levels of electrolytes, urea nitrogen, creatinine,
calcium, phosphorus, glucose, bilirubin, protein, alkaline phospha-
tase, lactate dehydrogenase, and transaminases in the serum .
Analysis ofBiopsies.
￿
Biopsies were divided longitudinally . One
portion was processed for Fite's stain and the other for immunocy-
tochemistry using the antibodies and methods described (7, 8,
10-12) .
Results
Concern about inducing severe reversal reactions dictated
a step-wise approach . First, three subjects with lepromatous
disease were given single intramuscular injections of 10 or
30 Wg ofrIFN-y/m2. There was no toxicity over subsequent
months, nor were histologic changes detected 2 d later at
a distant site (intradermal injection of rIFN-y induces local
histologic changes within this time [8]) . In the next eight
subjects, we increased the number of daily intramuscular
rIFN-,y injections to 10, giving 10 Ag/m 2 daily to the first
four, and 30 14g/ml to the next four. Because the latter dose
affected the skin so dramatically, we omitted a planned dose
of 100 wg/m2 . The following results pertain to the last eight
subjects .
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Clinically Evident Changes in the Skin.
￿
Plaques over the
entire body of one patient flattened during treatment with
rIFN-,y at the lower dose. Two patients at the higher dose
level showed faint, widespread erythema, which disappeared
when the injections were stopped . The other two patients
at the higher dose level displayed rapidly fluctuating cuta-
neous nodularity. Long-standing nodules shrank ; new nodules
appeared suddenly but transiently, often with overlying err
thema. When rIFN-,y injections were completed, changes
in nodularity ceased . There was no accompanying fever, pain,
or tenderness.
Immunohistologic Changes in the Skin .
￿
The response de-
scribedbelow were detected bilaterally, at several time points,
in skin remote from rIFN-,y injection sites or their lymphatic
drainage.
At the lower dose level, the dermis of two subjects showed
marked increases inMHC class II-positive cells andT lym-
phocytes, including cells bearing CD4, CD8, or CD1a (not
shown) . These changes were evident at day 3, more marked
at day 10, and present but diminished by the eighth week .
In another patient at the lower dose level, the dermis was
already heavily infiltrated with both T cells and macrophages ;
there was no obvious increase after rIFN-,y administration .
One subject showed scant mononuclear cell infiltration both
before and after administration of rIFN-y .
At the higher dose level, three of four subjects showed
a massive increase in the area involved by intradermal
MHC-positive class II mononuclear cells (Fig . 1, a-c) . The
increased infiltrate included both T cells (Fig. 1, d-J) and
mononuclear phagocytes (Fig . 1, g-h) . No granulocytes were
observed. Changes were evident by day 3 and progressed there-
after, persisting through the eighth week (Fig . 1 h) . The one
patient in whose skin no histologic changes were noted had
begun taking 60 mg of prednisone daily within a few days
of completing the rIFN-y injections (see below) .
In contrast to results at the sites of intradermal injection
of rIFN-y (7-10), keratinocytes were not induced to display
MHC class II antigens at either dose level (Fig . 1, a-c) ;
epithelioid cells became prominent in only one individual (not
shown) ; and the epidermis thickened in only three of the
eight subjects (one at the lower dose and two at the higher
dose ; Fig . 1 a vs. c, and g vs. h) .
Bacterial Burden.
￿
Onlytwo subjects had high initial bac-
terial indices (3) ; both received the lower dose of rIFN-y .
Changes in tow bacterial indices are difficult to evaluate, es-
pecially with small biopsy fragments . No changes were evi-
dent over the 8-wk study period .
Neurologic Responses and Other Clinical E,jects.
￿
Examina-
tion by a neurologist, and measurement of conduction ve-
locities in afflicted sensory nerves, were carried out immedi-
ately before the first injection and on the day after the last
injection of rIFN-y . No changes were detected. Before and
after entry to the study, five patients took clofazimine and/or
thalidomide to control nerve tenderness, dysesthesia, and/or
sensory impairment attributed to erythema nodosum lepro-
sum. Within 4 mo of rIFN-y treatment, a patient who had
recently been on prednisone resumed it; another subject started
it . In each case, signs and symptoms of neuritis resolved1511
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without further loss of function . Mild headaches and my-
algia after the initial injection of rIFN-y at the higher dose
were forestalled by administration of acetaminophen . No per-
sistent changes were noted in the blood tests listed in Materials
and Methods .
Discussion
Intradermal administration of rIFN-y to patients with
lepromatous leprosy (7) was, to our knowledge, the first at-
tempt to treat a nonviral infectious disease of man with a
recombinant product ofthe immune system . Subsequent trials
of rIFN-y in cutaneous leishmaniasis (13), visceral leishman-
iasis (14), and chronic granulomatous disease (15) have achieved
therapeutic or prophylactic success . In leprosy, however, no
evidence has yet emerged that benefit from cytokine therapy
can extend beyond the site of injection .
The present trial, though small, suggests that treatment
of lepromatous subjects with 10 daily intramuscular injec-
tions of rIFN-y at 10 or 30 lig/mz per day can lead in a
dose-dependent manner to generalized, intradermal mono-
nuclear cell infiltration . It seems remarkable that intramus-
cular injection of a single cytokine in amounts too small to
produce detectable serum levels can elicit complex histologic
changes that are remote from the sites of injection and that
persist for weeks after clearance of the injected agent . In vitro,
IFN-y can induce its own production (16) . Perhaps brief ex-
posure to small amounts of exogenous rIFN-y triggers sus-
tained production of endogenous IFN-y by cells in the le-
sions . The observed changes may also reflect the ability of
rIFN-y to induce and/or synergize with other cytokines . Fi-
nally, rIFN-y is pleiotropic, and may have served as a T or
NK cell differentiation factor, endothelial cell activator, and/or
monocyte chemotactin, as well as a macrophage activator (17) .
Treatment with rIFN-y by the regimen used here appeared
to be safe for patients with lepromatous leprosy receiving
standard chemotherapy. This was the case even for patients
requiring therapy for erythema nodosum leprosum at the time
ofadmission to the study. rIFN-ymay have exacerbated neu-
ritis in some patients, but given the natural history of the
disease, a cause-and-effect relationship was difficult to estab-
lish. More important, neuritis remained manageable after ad-
ministration of rIFN-y, and no further loss of function was
encountered in any of the 11 subjects. Follow-up has lasted
4.5 yr for patients receiving one injection, and 15.6 ± 3 .5
mo (mean ± SEM; range, 7-27 mo) for those receiving 10
injections.
Figure 1 .
￿
Immunocytochemical analysis of skin biopsies from the lower
back of an individual with lepromatous leprosy receiving a 10-d course
of30 #g/m2 rIFN-y daily in the triceps muscles. The epidermis is marked
by small arrows, andantigen-positive cells by large arrows. (a-c) Accumu-
lation ofMHC class II-positive cells. (a) Pre-treatment; (b) 10 d ; (c) 28 d
after onset of rIFN-y injections. (d-f ) Accumulation ofCD3+ T cells.
(d) Pretreatment; (e) day 28 ; (f) higher power view ofE to demonstrate
the association ofreaction product with individual cells. (g, b) Accumula-
tion of Leu-M5+ niononuclear phagocytes . (g) Pretreatment ; (h) day 51 .
(a-c, e, g, h)
￿
x 46; (d and f )
￿
x183 .In conclusion,rIFN-y caninduce a partial but widespread
reversal reaction of the upgrading variety in individuals with
lepromatous leprosy, without prohibitive toxicity. It should
now be tested if systemic administration of rIFN-y over
prolonged periods can increase the efficiency of antileprotic
chemotherapy.
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